An improvement in gross margins is on the cards over the next three to four quarters

Neutral Divis Labs; target of Rs 2620: Motilal Oswal

Motilal Oswal recommended Neutral rating on Divis Labs with a target price of Rs 2620 in its research report dated March 20, 2023.

Hold Divi’s Laboratories; target of Rs 3168: Sharekhan

Sharekhan recommended Hold rating on Divi’s Laboratories with a target price of Rs 3168 in its research report dated February 03, 2023.

Hold Divi's Laboratories; target of Rs 2945: ICICI Direct

ICICI Direct recommended hold rating on Divi's Laboratories with a target price of Rs 2945 in its research report dated February 03, 2023.

Pharma: Is the pandemic investment template about to play out?

The return of the flu season in India and the US, and COVID-19 in China sparked more investor interest in the sector.

Buy Divi’s Laboratories; target of Rs 3975: Sharekhan

Sharekhan is bullish on Divi’s Laboratories has recommended buy rating on the stock with a target price of Rs 3975 in its research report dated November 09, 2022.

Hold Divi's Laboratories; target of Rs 3685: ICICI Direct

ICICI Direct recommended hold rating on Divi's Laboratories with a target price of Rs 3685 in its research report dated November 08, 2022.

Hold Divi's Laboratories; target of Rs 3300: Prabhudas Lilladher

Prabhudas Lilladher recommended hold rating on Divi's Laboratories with a target price of Rs 3300 in its research report dated November 08, 2022.

Neutral Divi’s Laboratories; target of Rs 3250: Motilal Oswal

Motilal Oswal recommended Neutral rating on Divi’s Laboratories with a target price of Rs 3250 in its research report dated November 08, 2022.

Buy Divis Laboratories; target of Rs 4450: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4450 in its research report dated August 26, 2022.

Accumulate Divi's Laboratories; target of Rs 4140: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Divi's Laboratories with a target price of Rs 4140 in its research report dated August 15, 2022.

Buy Divis Laboratories; target of Rs 4450: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4450 in its research report dated August 12, 2022.

Divi’s Labs: Focus on green chemistry

The drug firm is set to benefit from investments in productivity and new product range

Buy Divi’s Laboratories; target of Rs 4340: Motilal Oswal

Motilal Oswal is bullish on Divi’s Laboratories recommended buy rating on the stock with a target price of Rs 4340 in its research report dated August 13, 2022.

Buy Divi's Laboratories; target of Rs 4315: ICICI Direct

ICICI Direct is bullish on Divi's Laboratories has recommended buy rating on the stock with a target price of Rs 4315 in its research report dated August 12, 2022.

Divi’s Labs: Steady margin profile amid cost headwind

Earnings trigger for the medium term is Contrast Media API opportunity, where there is limited competition

Buy Divis Laboratories: target of Rs 4900: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated May 23, 2022.

Buy Divi’s Laboratories; target of Rs 4480: Motilal Oswal

Motilal Oswal is bullish on Divi’s Laboratories recommended buy rating on the stock with a target price of Rs 4480 in its research report dated May 23, 2022.

Accumulate Divi's Laboratories; target of Rs 4300: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Divi's Laboratories with a target price of Rs 4300 in its research report dated May 24, 2022.

Buy Divi's Laboratories; target of Rs 4655: ICICI Direct

ICICI Direct recommended hold rating on Divi's Laboratories with a target price of Rs 4655 in its research report dated May 24, 2022.

Aether IPO | This niche chemical player is a leader of the pack. How?

The company’s success depends on identifying the molecule/product opportunity, investing behind R&D and implementing processes/integration to scale it up

Buy Divis Laboratories: target of Rs 5620: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 5620 in its research report dated March 09, 2022.

Hikal: Green integrity in the spotlight, more than financials

We are entering increasing interest rate scenario. Liquidity is drying which simply means institutional fund flows would be much more selective and sensitive to quality aspect

Divi’s Labs: Investment to improve yields provides the edge

Operating margins of Divi's are likely to remain elevated, given the benefits from the recent investments on improving yields and backward integration

Divi’s Lab: Green chemistry can set it apart

The management of Divi's Lab asserts that there are no Nitrosamine or Azido impurities in the company's Sartan API offerings.